$14 – $17

Rare Disease Therapies in CAN: Ensuring Access to Life-changing Innovations

Event Information

Share this event

Date and Time

Location

Location

Mad Crush Wine bar

582 College Street

Toronto, ON M5T 1P9

Canada

View Map

Refund Policy

Refund Policy

Refunds up to 7 days before event

Event description

Description

Science to Business Network Presents...

Rare Disease Therapies in Canada: Ensuring Access to Life-changing Innovations

Approximately 1 in 12 Canadians are affected by a rare disorder. As many as two-thirds are children. Some of the most cutting-edge research is being performed around these diseases and novel therapies based on new scientific insights are becoming a reality. However, access to new therapies and issues around who pays for these innovations is a significant concern as more of these promising therapies come to market. This session will seek to outline the challenges facing this growing sector within life sciences and healthcare and the identification of opportunities for researchers, policymakers, industry, and patients to contribute to a solution to foster appropriate incentives to innovate while ensuring sustainable access to promising new therapies.


Session Objectives:
  • Discuss trends in therapies for Rare Diseases nationally and globally
  • Outline how the current environment in Canada impacts innovation and drug access
  • Explore actions that will allow patients to gain access to life-changing therapeutics

Host: Bruce Seet, Ph.D, MBA

With Guest Panelists:

Durane Wong-Rieger, Ph.D. (President, Canadian Organization for Rare Diseases)
Bob McLay, MBA (General Manager, Sobi Canada)
Brian Jahns, PharmD (Sr. VP Commercialization and Business Development, Trillium Therapeutics)
Joost van der Mark, MBA (Chief Business Officer, 3D Signatures Inc.)



Wednesday, Feb. 28, 2018
Mad Crush Wine Bar
582 College St, Toronto

6:00 pm Event Registration
6:30 pm Panel Discussion + Q&A
7:30 pm Networking Reception (light snacks provided)

Tickets:
Online Early Bird - $14.00 + fees
Online Regular - $17.00 + fees
At the Door - $22.00

Panelist Biographies:

Durhane Wong-Rieger, Ph.D.

Durhane Wong-Rieger has served on numerous health policy advisory committees and panels and is a member of the Advisory Board for the Canadian Institutes of Health Research Institute of Genetics and the Patient Liaison Forum for the Canadian Drugs and Technologies in Health. Durhane is immediate Past-Chair of the International Alliance of Patient Organizations, and Board Member representing patient interests at DIA International Association. She has a PhD in psychology from McGill University.

Brian Jahns, PharmD

Dr. Jahns is Senior Vice-President of Commercial and Business Development at Trillium Therapeutics Inc, a Canadian-based clinical-stage immuno-oncology company dedicated to the discovery and development of innovative cancer therapies. He's responsible for providing commercial input into the Trillium clinical and regulatory strategy, as well as carrying out business development activities. He has an extensive background in the pharmaceutical and health care industry, most recently as Vice President Oncology and Vice President Product Strategy for Hoffmann-La Roche Canada. Dr. Jahns completed his B.Sc. and Pharm.D. at Wayne State University, and conducted his postdoctoral studies at the University of Illinois at Chicago before serving on the faculty of the University of Toronto School of Pharmacy.

Joost van der Mark, MBA

Mr. van der Mark is a seasoned healthcare executive with over two decades of experience in the biopharmaceutical industry and joined 3D Signatures as Chief Business Officer responsible for business development. Prior to joining 3D Signatures, Mr van der Mark served as the Vice President of Corporate Development of BioSyent Inc. responsible for the acquisition and licensing activities for the corporation. Mr van der Mark was co-founder and co-owner of Orphan Canada Inc. prior to it’s sale to Knight Therapeutics and prior to this had progressive positions at Nycomed (Takeda), Sanofi Pasteur and Bayer Mr. van der Mark holds an M.Sc. in Physiology and Pharmacology from the University of Western Ontario and an M.B.A. from Schulich School of Business.

Bob McLay, MBA

Bob McLay currently leads the Canadian affiliate of Sobi (Swedish Orphan Biovitrum AB), a specialty healthcare company dedicated to rare diseases. Prior to Sobi, Bob held multiple leadership roles in both large and small pharma companies including Pfizer, Takeda, Alcon, Merus Labs and Graceway.


Host Biography:

Bruce Seet, PhD, MBA

Bruce Seet is the founder and President of the Science to Business Network, a group dedicated to bridging academia, government and industry. He started his career in bio-pharmaceuticals in 2006 and held multiple roles at GlaxoSmithKline over 8 years. Since 2014, he has been Director, Medical Affairs, at Sanofi Pasteur Canada. He also holds the position of Adjunct Professor at the University of Toronto's Department of Molecular Genetics. Bruce earned a B.Sc (Honours Human Physiology) and a Ph.D. (Microbiology and Immunology) from Western University (London, Canada), followed by a postdoctoral research fellowship at the Lunenfeld Research Institute at Mt. Sinai Hospital (Toronto).



Share with friends

Date and Time

Location

Mad Crush Wine bar

582 College Street

Toronto, ON M5T 1P9

Canada

View Map

Refund Policy

Refunds up to 7 days before event

Save This Event

Event Saved